|
|
||||||||


* Research Laboratories of Schering AG, Experimental Oncology, 13342 Berlin, Germany; and
# Department of Cardiology and Pneumology and
Institute of Clinical Pharmacology and Toxicology, Benjamin Franklin Medical Center, Freie Universität Berlin, 12200 Berlin, Germany
1Correspondence: Benjamin Franklin Medical Center, Department of Cardiology and Pneumology, Hindenburgdamm 30 D-12200 Berlin, Germany. E-mail: thomas.walther{at}ukbf.fu-berlin.de
Angiotensin II (ANG II), a key regulator of blood pressure and body fluid homeostasis, exerts mitogenic effects on endothelial cells. We therefore hypothesized that ANG II could be a mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis. In the present study, we applied the alginate implant angiogenesis model in mice with normal ANG II levels, elevated ANG II levels by transgenic overexpression of angiotensinogen (AOGEN), or in AT2 receptor-deficient mice. We demonstrate that a decrease in the amount of circulating ANG II by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG II through the AT1 receptor. However, the strong increase of angiogenesis in AOGEN-transgenic mice compared with mice with normal ANG II levels suggests additional stimulatory activity. We showed that the ANG II-induced stimulation of angiogenesis is linked to the AT2 receptor as an impaired induction of angiogenesis was obtained in AT2 receptor knockout mice. These findings provide the first evidence that the AT2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ANG II is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions.Walther, W., Menrad, A., Orzechowski, H.-D., Siemeister, G., Paul, M., Schirner, M. Differential regulation of in vivo angiogenesis by angiotensin II receptors.
Key Words: alginate implant angiogenesis angiotensin receptor AT1 angiotensin receptor AT2
This article has been cited by other articles:
![]() |
R. Reed, C. Kolz, B. Potter, and P. Rocic The Mechanistic Basis for the Disparate Effects of Angiotensin II on Coronary Collateral Growth Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Hu, A. Dandapat, and J. L Mehta Angiotensin II Induces Capillary Formation From Endothelial Cells Via the LOX-1 Dependent Redox-Sensitive Pathway Hypertension, November 1, 2007; 50(5): 952 - 957. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Munk, L. Sanchez de Miguel, M. Petrimpol, N. Butz, A. Banfi, U. Eriksson, L. Hein, R. Humar, and E. J. Battegay Angiotensin II Induces Angiogenesis in the Hypoxic Adult Mouse Heart In Vitro Through an AT2-B2 Receptor Pathway Hypertension, May 1, 2007; 49(5): 1178 - 1185. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Rakusan, Z. Chvojkova, P. Oliviero, I. Ostadalova, F. Kolar, C. Chassagne, J.-L. Samuel, and B. Ostadal ANG II type 1 receptor antagonist irbesartan inhibits coronary angiogenesis stimulated by chronic intermittent hypoxia in neonatal rats Am J Physiol Heart Circ Physiol, March 1, 2007; 292(3): H1237 - H1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Feihl, L. Liaudet, B. Waeber, and B. I. Levy Hypertension: A Disease of the Microcirculation? Hypertension, December 1, 2006; 48(6): 1012 - 1017. [Full Text] [PDF] |
||||
![]() |
T. A. Barker, M. P. Massett, V. A. Korshunov, A. M. Mohan, A. J. Kennedy, and B. C. Berk Angiotensin II Type 2 Receptor Expression After Vascular Injury: Differing Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin Receptor Blockade Hypertension, November 1, 2006; 48(5): 942 - 949. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D'Amore, M. J. Black, and W. G. Thomas The Angiotensin II Type 2 Receptor Causes Constitutive Growth of Cardiomyocytes and Does Not Antagonize Angiotensin II Type 1 Receptor-Mediated Hypertrophy Hypertension, December 1, 2005; 46(6): 1347 - 1354. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Gonzalez-Zuloeta Ladd, A. Arias Vasquez, F. A. Sayed-Tabatabaei, J.W. Coebergh, A. Hofman, O. Njajou, B. Stricker, and C. van Duijn Angiotensin-Converting Enzyme Gene Insertion/Deletion Polymorphism and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2143 - 2146. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zheng, I. M. Bird, D.-B. Chen, and R. R. Magness Angiotensin II regulation of ovine fetoplacental artery endothelial functions: interactions with nitric oxide J. Physiol., May 15, 2005; 565(1): 59 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Rocken, U. Lendeckel, J. Dierkes, S. Westphal, S. Carl-McGrath, B. Peters, S. Kruger, P. Malfertheiner, A. Roessner, and M. P.A. Ebert The Number of Lymph Node Metastases in Gastric Cancer Correlates with the Angiotensin I-Converting Enzyme Gene Insertion/Deletion Polymorphism Clin. Cancer Res., April 1, 2005; 11(7): 2526 - 2530. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Watanabe, T. A. Barker, and B. C. Berk Angiotensin II and the Endothelium: Diverse Signals and Effects Hypertension, February 1, 2005; 45(2): 163 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-Y. Hsieh, C.-C. Chang, F.-J. Tsai, C.-M. Hsu, C.-C. Lin, and C.-H. Tsai Angiotensin I-converting enzyme ACE 2350*G and ACE-240*T-related genotypes and alleles are associated with higher susceptibility to endometriosis Mol. Hum. Reprod., January 1, 2005; 11(1): 11 - 14. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. McCarty Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380. [Abstract] [PDF] |
||||
![]() |
R. H.P. Hilgers, P. M.H. Schiffers, W. M. Aartsen, G. E. Fazzi, J. F.M. Smits, and J. G.R. De Mey Tissue Angiotensin-Converting Enzyme in Imposed and Physiological Flow-Related Arterial Remodeling in Mice Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 892 - 897. [Abstract] [Full Text] |
||||
![]() |
T. Ichiki Role of Renin Angiotensin System in Angiogenesis: It Is Still Elusive Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 622 - 624. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |